Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Neoplasms 2Lymphoma 2Lung Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Nose Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 10Doxorubicin 6tanespimycin 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Ifosfamide 5Etoposide 5Cyclosporine 5fludarabine phosphate 4Prednisone 4Methotrexate 4Cytarabine 4Carboplatin 4Bortezomib 4Antilymphocyte Serum 4Vorinostat 3Rituximab 3Methylprednisolone 3Leucovorin 3Irinotecan 3Gemcitabine 3Filgrastim 3Dexamethasone 3Busulfan 3Brentuximab Vedotin 3Biopsy 3Bevacizumab 3merphos 2laromustine 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large-Cell, Anaplastic × Positron-Emission Tomography × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡